BEIGENE Opens Over 3% Higher in Early Trading; CSCI Maintains "Buy" Rating

Deep News11-18

BEIGENE (06160) opened more than 3% higher in early trading. At the time of writing, the stock was up 3.53% to HK$223.2, with a turnover of HK$11.96 million.

On November 17, BEIGENE announced positive results from its Phase III HERIZON-GEA-01 study. The study evaluated the efficacy and safety of zanidatamab, a HER2-targeted bispecific antibody, either as a monotherapy or in combination with the PD-1 inhibitor tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including gastric, gastroesophageal junction, and esophageal cancers.

CSCI previously noted that BEIGENE's zanubrutinib continues to show strong sales growth, prompting an upward revision of its full-year performance guidance. Considering the company's better-than-expected overseas sales of BTK inhibitors, the launch and expansion of PD-1 drugs in markets such as the EU and Japan, and the continued commercialization of key pipelines like BCL-2, BTK CDAC, and CDK4, CSCI maintains its "Buy" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111797116?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111797116","market":"nz","top_or_hot":-1,"title":"BEIGENE Opens Over 3% Higher in Early Trading; CSCI Maintains \"Buy\" Rating","media":"Deep News","content":"<p>BEIGENE (06160) opened more than 3% higher in early trading. At the time of writing, the stock was up 3.53% to HK$223.2, with a turnover of HK$11.96 million.</p>\n<p>On November 17, BEIGENE announced positive results from its Phase III HERIZON-GEA-01 study. The study evaluated the efficacy and safety of zanidatamab, a HER2-targeted bispecific antibody, either as a monotherapy or in combination with the PD-1 inhibitor tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including gastric, gastroesophageal junction, and esophageal cancers.</p>\n<p>CSCI previously noted that BEIGENE's zanubrutinib continues to show strong sales growth, prompting an upward revision of its full-year performance guidance. Considering the company's better-than-expected overseas sales of BTK inhibitors, the launch and expansion of PD-1 drugs in markets such as the EU and Japan, and the continued commercialization of key pipelines like BCL-2, BTK CDAC, and CDK4, CSCI maintains its \"Buy\" rating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BEIGENE Opens Over 3% Higher in Early Trading; CSCI Maintains \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBEIGENE Opens Over 3% Higher in Early Trading; CSCI Maintains \"Buy\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-11-18 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIGENE (06160) opened more than 3% higher in early trading. At the time of writing, the stock was up 3.53% to HK$223.2, with a turnover of HK$11.96 million.</p>\n<p>On November 17, BEIGENE announced positive results from its Phase III HERIZON-GEA-01 study. The study evaluated the efficacy and safety of zanidatamab, a HER2-targeted bispecific antibody, either as a monotherapy or in combination with the PD-1 inhibitor tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including gastric, gastroesophageal junction, and esophageal cancers.</p>\n<p>CSCI previously noted that BEIGENE's zanubrutinib continues to show strong sales growth, prompting an upward revision of its full-year performance guidance. Considering the company's better-than-expected overseas sales of BTK inhibitors, the launch and expansion of PD-1 drugs in markets such as the EU and Japan, and the continued commercialization of key pipelines like BCL-2, BTK CDAC, and CDK4, CSCI maintains its \"Buy\" rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1251922891.USD","symbol_name":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1111797116","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111797116","pubTimestamp":1763430018,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"BEIGENE (06160) opened more than 3% higher in early trading. At the time of writing, the stock was up 3.53% to HK$223.2, with a turnover of HK$11.96 million. On November 17, BEIGENE announced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","ONC":"百济神州","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","06160":"百济神州","BK1161":"生物科技","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK1588":"回港中概股","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK4585":"ETF&股票定投概念","BK4526":"热门中概股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK4139":"生物科技","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","BK0239":"医药制造","BK1583":"高瓴概念","BK1500":"做空集合股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"百济神州早盘高开超3%；CSCI维持“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"06160":1,"ONC":1},"content_text":"BEIGENE (06160) opened more than 3% higher in early trading. At the time of writing, the stock was up 3.53% to HK$223.2, with a turnover of HK$11.96 million.\nOn November 17, BEIGENE announced positive results from its Phase III HERIZON-GEA-01 study. The study evaluated the efficacy and safety of zanidatamab, a HER2-targeted bispecific antibody, either as a monotherapy or in combination with the PD-1 inhibitor tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including gastric, gastroesophageal junction, and esophageal cancers.\nCSCI previously noted that BEIGENE's zanubrutinib continues to show strong sales growth, prompting an upward revision of its full-year performance guidance. Considering the company's better-than-expected overseas sales of BTK inhibitors, the launch and expansion of PD-1 drugs in markets such as the EU and Japan, and the continued commercialization of key pipelines like BCL-2, BTK CDAC, and CDK4, CSCI maintains its \"Buy\" rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111797116","isCrawlerRequest":true}